140 related articles for article (PubMed ID: 37679749)
1. Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort.
Wallimann M; Bouayed K; Cannizzaro E; Kaiser D; Belot A; Merlin E; Poignant S; Wouters C; Hofer F; Saurenmann T; Koryllou A; Carlomagno R; Mejbri M; Hofer M; Theodoropoulou K
Pediatr Rheumatol Online J; 2023 Sep; 21(1):96. PubMed ID: 37679749
[TBL] [Abstract][Full Text] [Related]
2. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
[TBL] [Abstract][Full Text] [Related]
3. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
4. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
5. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort.
Guzman J; Oen K; Huber AM; Watanabe Duffy K; Boire G; Shiff N; Berard RA; Levy DM; Stringer E; Scuccimarri R; Morishita K; Johnson N; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey SE; Bruns A; Roth J; Campillo S; Benseler S; Chédeville G; Schneider R; Tse SM; Bolaria R; Gross K; Feldman B; Feldman D; Cameron B; Jurencak R; Dorval J; LeBlanc C; St Cyr C; Gibbon M; Yeung RS; Duffy CM; Tucker LB;
Ann Rheum Dis; 2016 Jun; 75(6):1092-8. PubMed ID: 25985972
[TBL] [Abstract][Full Text] [Related]
6. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S; Dennos AC; Kimura Y; Beukelman T; Shrader P; Phillips TA; Kohlheim M; Schanberg LE; Yeung RSM; Horton DB;
Arthritis Care Res (Hoboken); 2023 Apr; 75(4):715-723. PubMed ID: 35921198
[TBL] [Abstract][Full Text] [Related]
7. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Baris HE; Anderson E; Sozeri B; Dedeoglu F
Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
[TBL] [Abstract][Full Text] [Related]
9. Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.
Arnstad ED; Rypdal V; Peltoniemi S; Herlin T; Berntson L; Fasth A; Nielsen S; Glerup M; Ekelund M; Zak M; Aalto K; Nordal E; Romundstad PR; Rygg M;
Arthritis Care Res (Hoboken); 2019 Jul; 71(7):961-969. PubMed ID: 30055093
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
11. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
Heiligenhaus A; Klotsche J; Tappeiner C; Sengler C; Niewerth M; Liedmann I; Hoeft S; Walscheid K; Lavric M; Foell D; Minden K
Rheumatology (Oxford); 2019 Jun; 58(6):975-986. PubMed ID: 30590748
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
[TBL] [Abstract][Full Text] [Related]
14. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
[TBL] [Abstract][Full Text] [Related]
15. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
17. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden.
Berthold E; Månsson B; Kahn R
Arthritis Res Ther; 2019 Oct; 21(1):218. PubMed ID: 31661011
[TBL] [Abstract][Full Text] [Related]
18. Variation in Treatment of Children Hospitalized With New-Onset Systemic Juvenile Idiopathic Arthritis in the US.
Peterson RG; Xiao R; James KE; Katcoff H; Fisher BT; Weiss PF
Arthritis Care Res (Hoboken); 2021 Dec; 73(12):1714-1721. PubMed ID: 33242366
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade.
Teh KL; Tanya M; Das L; Hoh SF; Gao X; Arkachaisri T
Clin Rheumatol; 2021 Jun; 40(6):2339-2349. PubMed ID: 33236179
[TBL] [Abstract][Full Text] [Related]
20. Ankle arthritis predicts polyarticular disease course and unfavourable outcome in children with juvenile idiopathic arthritis.
Esbjörnsson AC; Aalto K; Broström EW; Fasth A; Herlin T; Nielsen S; Nordal E; Peltoniemi S; Rygg M; Zak M; Berntson L;
Clin Exp Rheumatol; 2015; 33(5):751-7. PubMed ID: 26213158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
